Toll-Like Receptor-4 Promotes the Development of Colitis-Associated Colorectal Tumors

Gastroenterology

Volumn 133, Issue 6, 2007, Pages

  Fukata, Masayuki ^a   Chen, Anli ^a   Vamadevan, Arunan S ^a   Cohen, Jason ^a   Breglio, Keith ^a   Krishnareddy, Suneeta ^a   Hsu, David ^a   Xu, Ruliang ^a   Harpaz, Noam ^a   Dannenberg, Andrew J ^b   Subbaramaiah, Kotha ^b   Cooper, Harry S ^c   Itzkowitz, Steven H ^a   Abreu, Maria T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; AZOXYMETHANE; CYCLOOXYGENASE 2; DEXTRAN SODIUM SULFATE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROSTAGLANDIN E2; SODIUM SULFATE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER PREVENTION; CANCER THERAPY; CHRONIC INFLAMMATION; COLON CARCINOGENESIS; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; DYSPLASIA; ENZYME IMMUNOASSAY; ENZYME INDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; INJECTION; INTESTINE POLYP; MALE; MOUSE; MUCOSA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS; WESTERN BLOTTING; WILD TYPE;

EID: 36549082403     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.09.008     Document Type: Article

References (48)

1. Sin D.D., Man S.F., McWilliams A., et al. Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer. Am J Respir Crit Care Med 173 (2006) 535-539
2. Rao V.P., Poutahidis T., Ge Z., et al. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res 66 (2006) 7395-7400
3. Gunter M.J., Stolzenberg-Solomon R., Cross A.J., et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 66 (2006) 2483-2487
4. Surveillance, Epidemiology, and End Results (SEER) Program and the National Center for Health Statistics. Available at: http://seer.cancer.gov/cgi-bin/twbsearch?pr-seer&query-colorect& template-%2Fsearch%2Findex.htm.
5. Itzkowitz S.H., and Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol 287 (2004) G7-G17
6. Eaden J.A., Abrams K.R., and Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48 (2001) 526-535
7. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126 (2004) 451-459
8. Gupta R.B., Harpaz N., Itzkowitz S., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133 (2007) 1099-1105
9. Greten F.R., Eckmann L., Greten T.F., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
10. Hope M.E., Hold G.L., Kain R., et al. Sporadic colorectal cancer-role of the commensal microbiota. FEMS Microbiol Lett 244 (2005) 1-7
11. Wang X., and Huycke M.M. Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells. Gastroenterology 132 (2007) 551-561
12. Sellon R.K., Tonkonogy S., Schultz M., et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66 (1998) 5224-5231
13. Kado S., Uchida K., Funabashi H., et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. Cancer Res 61 (2001) 2395-2398
14. Abreu M.T., Vora P., Faure E., et al. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 167 (2001) 1609-1616
15. Otte J.M., Cario E., and Podolsky D.K. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology 126 (2004) 1054-1070
16. Hausmann M., Kiessling S., Mestermann S., et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 122 (2002) 1987-2000
17. Cario E., Gerken G., and Podolsky D.K. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology 127 (2004) 224-238
18. Fukata M., Chen A., Klepper A., et al. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 131 (2006) 862-877
19. Huang B., Zhao J., Li H., et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65 (2005) 5009-5014
20. Wang D., Mann J.R., and DuBois R.N. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128 (2005) 1445-1461
21. Dannenberg A.J., Lippman S.M., Mann J.R., et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23 (2005) 254-266
22. Okayasu I., Ohkusa T., Kajiura K., et al. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 39 (1996) 87-92
23. Fukata M., Michelsen K.S., Eri R., et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol 288 (2005) G1055-G1065
24. Cooper H.S., Murthy S., Kido K., et al. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 21 (2000) 757-768
25. Morteau O., Morham S.G., Sellon R., et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest 105 (2000) 469-478
26. Abreu M.T., Vora P., Faure E., et al. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 167 (2001) 1609-1616
27. Abreu M.T., Arnold E.T., Thomas L.S., et al. TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem 277 (2002) 20431-20437
28. Cario E., and Podolsky D.K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 68 (2000) 7010-7017
29. Suzuki R., Kohno H., Sugie S., et al. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis 27 (2006) 162-169
30. Itzkowitz S.H., and Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126 (2004) 1634-1648
31. Rumio C., Besusso D., Arnaboldi F., et al. Activation of smooth muscle and myenteric plexus cells of jejunum via Toll-like receptor 4. J Cell Physiol 208 (2006) 47-54
32. Suganuma M., Okabe S., Marino M.W., et al. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 59 (1999) 4516-4518
33. Castellone M.D., Teramoto H., Williams B.O., et al. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310 (2005) 1504-1510
34. Pai R., Soreghan B., Szabo I.L., et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8 (2002) 289-293
35. Buchanan F.G., Wang D., Bargiacchi F., et al. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278 (2003) 35451-35457
36. Shao J., Lee S.B., Guo H., et al. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 63 (2003) 5218-5223
37. Moraitis D., Du B., De Lorenzo M.S., et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 65 (2005) 664-670
38. Kawahara T., Teshima S., Oka A., et al. Type I Helicobacter pylori lipopolysaccharide stimulates Toll-like receptor 4 and activates mitogen oxidase 1 in gastric pit cells. Infect Immun 69 (2001) 4382-4389
39. Termeer C., Benedix F., Sleeman J., et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 195 (2002) 99-111
40. de Visser K.E., Eichten A., and Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6 (2006) 24-37
41. Subbaramaiah K., Yoshimatsu K., Scherl E., et al. Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. J Biol Chem 279 (2004) 12647-12658
42. Otani T., Yamaguchi K., Scherl E., et al. Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha. Am J Physiol 290 (2006) G361-G368
43. Brown S.L., Riehl T.E., Walker M.R., et al. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J Clin Invest 117 (2007) 258-269
44. Coffey R.J., Hawkey C.J., Damstrup L., et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A 94 (1997) 657-662
45. Kohno H., Suzuki R., Sugie S., et al. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 5 (2005) 46
46. Ii M., Matsunaga N., Hazeki K., et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylat e (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol 69 (2006) 1288-1295
47. Arber N., Eagle C.J., Spicak J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 (2006) 885-895
48. Bertagnolli M.M., Eagle C.J., Zauber A.G., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 (2006) 873-884